Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02736149 · ClinicalTrials.gov registry record · Phase 2
Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)
A Phase 2 study, sponsored by Eiger BioPharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 51
- Enrollment target
NCT02736149 is a Phase 2 study that was terminated before completion, run by Eiger BioPharmaceuticals. The registered enrollment target is 51 participants.
The verdict
NCT02736149, a Phase 2 study, was terminated before completion, sponsored by Eiger BioPharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 51 participants
- Enrollment target
Study Summary
Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) to improve exercise capacity and delay clinical worsening. This study is a Phase 2, open-label, extension study to evaluate long-term safety and efficacy of ubenimex in patients with PAH (WHO Group 1) who complete Study EIG-UBX-001.
Interventions
- DRUG ubenimex
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 51 participants |
| Start Date | 2016-12 |
| Est. Completion | 2018-08 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02736149
The ClinicalTrials.gov registry entry for NCT02736149 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 51 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eiger BioPharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which ubenimex is the first listed.
NCT02736149 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02736149 about?
NCT02736149 is a clinical study titled "Open-Label Extension Study of Ubenimex in Patients With Pulmonary Arterial Hypertension (WHO Group 1)". Ubenimex is being developed for the treatment of pulmonary arterial hypertension (PAH) (World Health Organization \[WHO\] Group 1) to improve exercise capacity and delay clinical worsening. This study is a Phase 2, open-label, extension study to evaluate long-term safety and efficacy of ubenimex in...
What is the current status of trial NCT02736149?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 51 participants. The study started on 2016-12. Estimated completion is 2018-08.
What interventions are being tested in trial NCT02736149?
The interventions under investigation include: ubenimex (DRUG).
Who is sponsoring clinical trial NCT02736149?
This trial is sponsored by Eiger BioPharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.